Head and Neck Primary Mucosal Melanoma: Report of 17 Cases


Introduction: Mucosal melanoma (MM) is a rare disease, accounting for 1.7% - 3% of all melanomas and 8% of all head and neck melanomas. It’s a rare cancer with a very poor prognosis. Materials and Methods: We retrospectively reviewed the records of 17 patients with primary mucosal melanomas of the head and neck who were diagnosed between January 2007 and December 2012. Results: Our patient population included 9 women and 8 men. The age ranged from 61 to 75 years. The primary site of disease was in the sinonasal cavity for 12 patients (70%) and oral cavity for 5 patients. Treatment modalities for mucosal melanoma include surgical resection with or without neck dissection, immunochemotherapy, and radiation therapy (RT). 15 patients had attempted curative resections. Two patients received palliative radiation therapy as the primary treatment and chemotherapy as the adjuvant treatment. Discussion: Primary mucosal melanoma is a rare cancer and represents only 1.7% - 3% of all primary melanomas [1]-[3]. Mucosal melanoma must always be considered for multimodality therapy: surgical excision, medical oncology, and radiation therapy. Despite its radioresistant nature of tumor, the role of radiation therapy following surgical intervention has typically been advocated.

Share and Cite:

Belhoucha, B. , Essaadi, Z. , Rochdi, Y. , Nouri, H. , Aderdour, L. , Khouchani, M. and Raji, A. (2015) Head and Neck Primary Mucosal Melanoma: Report of 17 Cases. International Journal of Otolaryngology and Head & Neck Surgery, 4, 86-93. doi: 10.4236/ijohns.2015.42016.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Shashanka, R. and Smitha, B.R. (2012) Head and Neck Melanoma. International Scholarly Research Network ISRN Surgery, 2012, Article ID: 948302.
[2] Greenberg, M.S. and Glick, K.M. (2008) Pigmented Lesions of the Oral Mucosa. In: Burket’s Oral Medicine, 11th Edition, BC Decker, Hamilton, 586.
[3] Narasimhan, K., et al. (2009) Sinonasal Mucosal Melanoma: A 13-Year Experience at a Single Institution. Skull Base, 19, 255-262.
[4] Rapidis, A., Apostolidis, C., Vilos, G. and Valsamis, S. (2003) Primary Malignant Melanoma of the Oral Mucosa. Journal of Oral and Maxillofacial Surgery, 61, 1132-1139.
[5] Gavriel, H., McArthur, G., Sizeland, A. and Henderson, M. (2011) Review: Mucosal Melanoma of the Head and Neck. Melanoma Research, 21, 257-266.
[6] Chang, A., Karnell, L. and Menck, H. (1998) The National Cancer Data Base Report on Cutaneous and Noncutaneous Melanoma: A Summary of 84,836 Cases from the Past Decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer, 83, 1664-1678.
[7] Jethanamest, D., Vila, P.M., Sikora, S.G. and Morris, L.G.T. (2011) Predictors of Survival in Mucosal Melanoma of the Head and Neck. An-nals of Surgical Oncology, 18, 2748-2756.
[8] Leong, S.P., Accortt, N.A., Essner, R., Ross, M., Gershenwald, J.E., Pockaj, B., et al. (2006) Impact of Sentinel Node Status and Other Risk Factors on the Clinical Outcome of Head and Neck Melanoma Patients. Archives of Otolaryngology—Head Neck Surgery, 132, 370-373.
[9] Gaze, M.N., Kerr, G.R. and Smyth, J.F. (1990) Mucosal Melanomas of the Head and Neck: The Scottish Experience. The Scottish Melanoma Group. Clinical Oncology (Royal College of Radiolo-gists), 2, 277-283.
[10] Benlyazid, A., Thariat, J., Temam, S., Malard, O., Florescu, C., Choussy, O., et al. (2010) Postoperative Radiotherapy in Head and Neck Mucosal Melanoma: A GETTEC Study. Archives of Otolaryngology—Head Neck Surgery, 136, 1219-1225.
[11] Owens, J.M., Roberts, D.B. and Myers, J.N. (2003) The Role of Postoperative Adjuvant Radiation Therapy in the Treatment of Mucosal Melanomas of the Head and Neck Region. Archives of Otolaryngology—Head Neck Surgery, 129, 864-868.
[12] Wagner, M., Morris, C.G., Werning, J.W. and Mendenhall, W.M. (2008) Mucosal Melanoma of the Head and Neck. American Journal of Clinical Oncology, 31, 43-48.
[13] Hodi, F.S., Friedlander, P., Corless, C.L., Heinrich, M.C., Mac Rae, S., Kruse, A., et al. (2008) Major Response to Imatinib Mesylate in KIT-Mutated Melanoma. Journal of Clinical Oncology, 26, 2046-2051.
[14] Quintás-Cardama, A., Lazar, A.J., Woodman, S.E., Kim, K., Ross, M. and Hwu, P. (2008) Complete Response of Stage IV Anal Mucosal Melanoma Expressing KIT Val560Asp to the Multikinase Inhibitor Sorafenib. Nature Clinical Practice Oncology, 5, 737-740.
[15] Handolias, D., Salemi, R., Murray, W., Tan, A., Liu, W., Viros, A., et al. (2010) Mutations in KIT Occur at Low Frequency in Melanomas Arising from Anatomical Sites Associated with Chronic and Intermittent Sun Exposure. Pigment Cell Melanoma Research, 23, 210-215.

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.